Circassia Pharmaceuticals (NIOX) Stock Statistics & Valuation Metrics

Circassia Pharmaceuticals has a market cap or net worth of £297.46M. The enterprise value is 235.23M.

Circassia Pharmaceuticals has 417,783,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Circassia Pharmaceuticals’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.50%.

The current PE Ratio of Circassia Pharmaceuticals is 80.9. Circassia Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Circassia Pharmaceuticals had revenue of 41.80M and earned 3.70M in profits. Earnings per share was 0.01.

In the last 12 months, operating cash flow was 17.60M and capital expenditures 0.00, giving a free cash flow of 17.60M billion.

Circassia Pharmaceuticals pays an annual dividend of 125p, resulting in a dividend yield of 3.16%

Circassia Pharmaceuticals upcoming earnings date is Sep 11, 2025, Before Open (Confirmed).

Circassia Pharmaceuticals as a current ratio of 2.60, with Debt / Equity ratio of 2.52%

In the past 12 months, Circassia Pharmaceuticals has paid 4.40M in taxes.

Circassia Pharmaceuticals EV to EBITDA ratio is 2.16K, with an EV/FCF ratio of 1.63K.

Circassia Pharmaceuticals has £10.90M in cash and marketable securities with £1.50M in debt, giving a net cash position of -£9.40M billion.

Gross margin is 67.22%, with operating margin of 18.42%, and net profit margin of 8.85%.

The average price target for Circassia Pharmaceuticals is £77.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy